Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.47 |
| ▸ | GPR39 | O43194 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793117 | 0.86 | HRH4 (0.49) | HRH4GPR39CD274PIM1HRH3 | |
| SCHEMBL6536475 | 0.80 | HRH4 (0.47) | HRH4GPR39CD274S1PR1 | |
| SCHEMBL5353908 | 0.78 | CHEK1 (0.54) | HRH4GPR39CD274PIM1CHEK1 | |
| SCHEMBL25986477 | 0.78 | CHEK1 (0.54) | HRH4GPR39CD274CHEK1CHEK2 | |
| SCHEMBL5352046 | 0.71 | GRIN2B (0.72) | — | |
| SCHEMBL28267685 | 0.70 | MALT1 (0.41) | HRH4MEN1PIM1CAMK2DKMT2A | |
| SCHEMBL15114903 | 0.69 | EGFR (0.46) | HRH4CD274 | |
| SCHEMBL23028647 | 0.69 | MCHR1 (0.45) | MEN1PIM1CAMK2DHRH3KMT2A | |
| SCHEMBL2580117 | 0.69 | HRH4 (0.56) | HRH4GPR39MEN1CHEK1CHEK2 | |
| SCHEMBL1774715 | 0.69 | HRH4 (0.68) | HRH4GPR39CHEK1CHEK2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071492-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071492-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | HRH4 3526/4885GPR39 2968/4885MEN1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.